Charles River director James Foster sells $8.4 million in shares

James C. Foster, a Director at CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (NASDAQ:CRL), engaged in significant stock transactions on October 22, 2026, according to a recent filing.

Mr. Foster acquired 24,042 shares of common stock at a price of $244.41 per share, totaling $5,876,105. Concurrently, he sold 24,042 shares of the company’s common stock at $350.00 per share, for a total value of $8,414,700. This sale was executed pursuant to a Rule 10b5-1 trading plan, which was initially adopted on March 6, 2026.The timing of the sale comes as CRL shares trade near their 52-week high of $357.77, with the stock currently at $357.27. According to InvestingPro analysis, the stock appears overvalued relative to its Fair Value, placing it among the most overvalued stocks tracked by the platform. The company’s shares have surged over 108% in the past six months, with earnings results due in eight days on November 4.

The acquisition of shares stemmed from the exercise of stock options, allowing Mr. Foster to buy 24,042 shares at an exercise price of $244.41. These options became exercisable on May 27, 2023, and are set to expire on May 27, 2032. Following these transactions, Mr. Foster directly holds 31,596 shares of Charles River Laboratories common stock.

In addition to his direct holdings, Mr. Foster also maintains indirect beneficial ownership of common stock through various trusts: 5,423 shares via a 2024 GRAT, 10,780 shares via a 2025 GRAT, 20,000 shares via a 2026 GRAT, 10,000 shares through a trust held by his spouse, and 155,611 shares through another trust.

In other recent news, Charles River Laboratories International Inc. has been the focus of several analyst updates. UBS resumed coverage on the company with a buy rating, citing the market’s underestimation of earnings benefits from internalizing non-human primate supply, which is expected to enhance operating margins and earnings per share. Jefferies also maintained a buy rating while raising its price target to $340, highlighting the company’s long-term revenue growth and cost efficiency plans. TD Cowen increased its price target to $325, projecting 5% to 7% organic revenue growth and low double-digit percentage growth in adjusted earnings per share through 2030. Meanwhile, Mizuho adjusted its price target to $295 after Charles River Labs introduced intermediate-term financial targets at its Investor Day. These recent developments reflect a positive outlook from analysts regarding the company’s growth and financial strategies.